Study of the combination of Binimetinib and Encorafenib in adolescent patients with unresectable or Metastatic BRAF V600-mutant Melanoma
Study of the combination of Binimetinib and Encorafenib in adolescent patients with unresectable or Metastatic BRAF V600-mutant Melanoma
Advanced melanoma
Study of the combination of Binimetinib and Encorafenib in adolescent patients with unresectable or Metastatic BRAF V600-mutant Melanoma
Status
Status :
Active not recruiting
Type of study
Phase I
Min. Age
12
Years old
Max. Age
17
Years old
Gender
All
Therapeutic area :
Oncology
Disease :
Melanoma
Study medication :
Encorafenib (BRAFTOVI®) - Binimetinib (MEKTOVI®)
Phase :
Phase I
Start Date :
03 August 2020
End date :
05 September 2025
Study ID :
ARRAY-162-115
CT.gov Number :
NCT03878719
Send by email